Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2026 | $24.00 | Buy → Neutral | Rothschild & Co Redburn |
| 1/22/2026 | $21.00 | Buy → Hold | TD Cowen |
| 1/7/2026 | $75.00 | Outperform | Oppenheimer |
| 10/7/2025 | $40.00 | Overweight | Cantor Fitzgerald |
| 10/8/2024 | $86.00 | Buy | Redburn Atlantic |
| 6/17/2024 | $88.00 | Buy | Truist |
| 5/24/2024 | $86.00 → $73.00 | Buy | H.C. Wainwright |
| 5/23/2024 | $60.00 | Buy | Deutsche Bank |
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
6-K - Legend Biotech Corp (0001801198) (Filer)
4 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
3 - Legend Biotech Corp (0001801198) (Issuer)
Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignanciesAn ORR of 100% (6/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5/6) in patients with relapsed/ refractory NHLData demonstrate robust in vivo CAR-T expansion without lymphodepleting chemotherapy Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS <Grade 2 BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501,
LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78.6%, with durable responses seen in some patients New CARVYKTI® data continue to support durable efficacy and a consistent safety profile in multiple myeloma BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and AustraliaAdvanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026Cash and cash equivalents, and time deposits of $834.6 million, as of March 31, 2026. SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highl
Rothschild & Co Redburn downgraded Legend Biotech from Buy to Neutral and set a new price target of $24.00
TD Cowen downgraded Legend Biotech from Buy to Hold and set a new price target of $21.00
Oppenheimer initiated coverage of Legend Biotech with a rating of Outperform and set a new price target of $75.00
SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately. Mr. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025. Mr. Santos is a seasoned finance executive who has led financial operations in the pharmaceutical and technology sectors across the United States, Latin America, Europe, the Middle East, and Africa. At Legend, he will oversee financial operations to work to ensure a robust balance sheet and achieve and maintain profitability. "On behalf
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg
SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following recent launches in Italy, Poland, the Czech Republic, and AustraliaAdvanced early-stage cell therapy portfolio, with multiple data presentations expected at medical conferences in 2026Cash and cash equivalents, and time deposits of $834.6 million, as of March 31, 2026. SOMERSET, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2026 unaudited financial results and key corporate highl
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12, 2026, to review first quarter 2026 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients treated with CARVYKTI®CARVYKTI now available across 294 sites worldwide; continued expansion in U.S. community settingsAdvanced early-stage cell therapy portfolio, including first-patient dosing of in vivo candidates and presentation of first-in-human results for LUCAR-G39D, an allogeneic CAR-T therapy Cash and cash equivalents, and time deposits of $949 million, as of December 31, 2025 SOMERSET, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)
SC 13G/A - Legend Biotech Corp (0001801198) (Subject)